APT’s PhageBank and related technologies were exclusively licensed to APT from the U.S. military’s Biological Defense Research Directorate (BDRD), and leverage an ever-expanding library of phages that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank phage are matched through a proprietary phage susceptibility test (PST) being commercialized with Mayo Clinic Laboratories (MCL) on a global scale. PhageBank is positioned to be the first antimicrobial therapy to continually increase in spectrum of coverage over time and therefore does not require revenue suppressing antibiotic stewardship. PhageBank required technological breakthroughs in several areas including genomics, bacteriophage purification, machine vision, machine learning (artificial intelligence), and years of phage collection by the U.S. Military. APT’s in-house manufacturing and phage matching technology has already been leveraged to treat over 30 patients under FDA-approved compassionate use.